Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE-MM2 trial.
Richardson PG, Facon T, Venner CP, Bahlis NJ, Offner F, White D, Karlin L, Benboubker L, Voog E, Yoon SS, Suzuki K, Shibayama H, Zhang X, Villarreal M, Twumasi-Ankrah P, Labotka R, Rifkin RM, Lonial S, Kumar SK, Rajkumar SV, Moreau P.
Richardson PG, et al. Among authors: labotka r.
EJHaem. 2023 Aug 3;4(4):995-1005. doi: 10.1002/jha2.759. eCollection 2023 Nov.
EJHaem. 2023.
PMID: 38024593
Free PMC article.